sponsored
PatientsVille.com Logo

PatientsVille

Aluminium Medical Research Studies

Up-to-date List of Aluminium Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Aluminium Medical Research Studies

Rank Status Study
1 Recruiting Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
Condition: Contact Dermatitis
Intervention: Biological: Mercury, Aluminum, Palladium
Outcome Measures: Percentage of Participants who exhibit Positive Responses to each Allergen Concentration;   Percentage of Participants who exhibit Irritation (tape reaction), Itching and/or Burning Resulting from Application of the Investigational and Reference Allergen Panels
2 Not yet recruiting Safety, Tolerability, and Efficacy Study of Prophylactic Streptococcus Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Conditions: Pneumococcal Infections;   Streptococcus Pneumoniae;   Pneumonia, Pneumococcal
Interventions: Biological: GEN-004 with Aluminum Hydroxide Adjuvant;   Biological: Placebo
Outcome Measures: Efficacy of GEN-003 as measured by reduction in nasopharyngeal colonization;   Evaluation of the safety and tolerability of GEN-004 with aluminum hydroxide as measured by frequency and severity of Adverse Events;   Evaluation of the duration of S. pneumoniae colonization through 14 days after inoculation;   Evaluation of the immunogenicity of GEN-004 with aluminum hydroxide, as measured by TH17 (IL-17) and IgG responses to the antigens.
3 Recruiting Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis
Condition: Onychomycosis
Interventions: Device: Er:YAG laser + amorolfine lacquer;   Drug: Amorolfine lacquer
Outcome Measures: Extent of nail plate damage;   Mycological cure;   Clinical cure
4 Not yet recruiting Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
Condition: Campylobacter Infection
Interventions: Biological: Capsule-Conjugate Campylobacter Vaccine (CJCV1);   Drug: Alhydrogel®, aluminum hydroxide adjuvant (alum)
Outcome Measures: Presence of local and/or systemic reactogenicity;   Antibody titers against CJCV1 using enzyme-linked immunosorbent assay (ELISA);   Vaccine-specific IgA antibody-secreting cell (ASC) responses
5 Recruiting Tepilta® Versus Oxetacaine, Antacids and Placebo
Condition: Radiation-induced Oesophagitis
Interventions: Drug: oxetacaine, Aluminium and magnesium hydroxide;   Drug: oxetacaine;   Drug: magnesium and Aluminium hydroxide;   Other: Vehicle
Outcome Measures: Time from randomisation to requirement of additional systemic pain medication for oesophagitis (ASPO).;   ASPO: WHO analgesic pain ladder;   Pain intensity recorded on NRS with scores 0-10;   Swallowing disorder recorded on NRS with scores 0-10;   Adapted CTCAE grade;   Incidence of artificial nutrition due to radiation-induced oesophagitis;   Incidence of interruptions of radiation therapy due to radiation-induced oesophagitis;   Duration of pain medication intake after the end of Radiation Therapy;   Loss of body weight
6 Not yet recruiting Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children
Condition: Norovirus
Interventions: Biological: GI.1/GII.4 (15/15) - MPL (50);   Biological: GI.1/GII.4 (15/50) - MPL (50);   Biological: GI.1/GII.4 (50/50) - MPL (50);   Biological: GI.1/GII.4 (15/15) - MPL (15);   Biological: GI.1/GII.4 (15/50) - MPL (15);   Biological: GI.1/GII.4 (50/50) - MPL (15);   Biological: GI.1/GII.4 (15/15);   Biological: GI.1/GII.4 (15/50);   Biological: GI.1/GII.4 (50/50);   Biological: GI.1/GII.4 (50/150);   Biological: GI.1/GII.4 (15/50) - Al(OH)3 (167);   Drug: Placebo
Outcome Measures: Percentage of Participants with a Seroresponse (Pan-Ig ELISA);   Percentage of Participants with Solicited Local Adverse Events (AEs) at Injection Site;   Percentage of Participants with Solicited Systemic Adverse Events (AEs);   Body Temperature Through Day 8 after each Vaccination;   Percentage of Participants with Unsolicited Adverse Events (AEs);   Percentage of Participants with Serious Adverse Events (SAEs);   Percentage of Participants with a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA);   Percentage of Participants with a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA);   Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA);   Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA);   Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA);   Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA);   Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA);   Percentage of Participants with Any Adverse Event (AE) Leading to Withdrawal from the Study;   Percentage of Participants with Adverse Events of Special Interest (AESI)
7 Recruiting Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Condition: Norovirus
Interventions: Biological: Hepatitis A Vaccine;   Biological: Norovirus Bivalent VLP Vaccine
Outcome Measures: Percentage of Participants with a Serorsponse (Pan-Ig ELISA);   Percentage of Participants with Solicited Local Adverse Events (AEs) at Injection Site;   Percentage of Participants with Solicited Systemic Adverse Events (AEs);   Oral Body Temperature over 7 Days after each Vaccination;   Percentage of Participants with Unsolicited Adverse Events (AEs);   Percentage of Participants with Serious Adverse Events (SAEs);   Percentage of Participants with a Seroresponse on Day 28, Day 208 and Day 393 (Pan-Ig ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in GI.1 VLP Antibody Titer (Pan-Ig ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in GII.4 VLP Antibody Titer (Pan-Ig ELISA);   Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA);   Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA);   Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA);   Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA);   Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP(HBGA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA);   Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA);   Blocking Titers 50 (BT50) of GII.4 VLP Antibody Titers (HBGA);   Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA);   Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA);   GMFR and BT50 of Antibody Titers of Strains not Represented in the Investigational Vaccine (HBGA);   Percentage of Participants with Significant New Medical Conditions;   Percentage of Participants with Any Adverse Event (AE) Leading to Withdrawal from the Study
8 Unknown  A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso
Condition: Malaria
Interventions: Biological: MSP 3 Long Synthetic Peptide;   Biological: Hepatitis B vaccine;   Biological: Hepatitis B control vaccince
Outcome Measures: Immediate reactogenicity (within 1 hour, with emphasis on allergic reactions);   Local and systemic reactogenicity during the 7 days following the vaccine;   Unsolicited adverse events occurring within 28 days following each vaccination;   Serious adverse events (SAE) throughout the study period;   Humoral immune responses by ELISA before and four weeks after each vaccination;   Cellular immune response to the vaccine antigens by measuring the;   number of cells producing IFNγ/106 cells by Elispot to MSP3-LSP and
9 Unknown  Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine
Condition: Malaria
Interventions: Biological: MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP;   Biological: Verorab vaccine
Outcome Measures: Number of clinical malaria episodes occurring during the consecutive malaria transmission season after the third vaccination;   Solicited adverse events measured from day 0 to day 7 after each dose;   Unsolicited adverse events measured up to one month after each dose;   Serious Adverse Events measured during the 12 months of study duration;   The humoral response to the vaccine antigen: assessed by measuring the level of IgG by ELISA;   IgG ability to recognize the native protein on Merozoite using Western Blot(WB) method;   Incidence of all clinical malaria episodes occurring through two transmission seasons subsequent to the 3 doses.
10 Unknown  Comparison of Splinting Interventions for Treating Mallet Finger Injuries
Condition: Mallet Finger
Interventions: Device: Circumferential thermoplastic thimble splint;   Device: dorsal Aluminium foam "Mexican Hat" splint;   Device: stack splint (control)
Outcome Measures: Degree of extensor lag at distal inter-phalangeal (DIP)joint;   Active range of motion at DIP;   Patient compliance with splinting regime, based on self-report (as described above);   Patient satisfaction with result on 5-point likert scale;   Complications;   Pain, measured by 10 point Visual Analogue Scale
11 Unknown  Aluminum and Auditory Function in ESRD
Condition: End-Stage Renal Disease (ESRD)
Intervention:
Outcome Measure:
12 Not yet recruiting Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults
Condition: Norovirus
Interventions: Biological: Norovirus Bivalent VLP Vaccine;   Drug: Placebo (Saline)
Outcome Measures: Percentage of Participants with Solicited Local Adverse Events (AEs) at Injection Site;   Percentage of Participants with Solicited Systemic Adverse Events (AEs);   Percentage of Participants with Elevated Daily Oral Temperature;   Percentage of Participants with Unsolicited Adverse Events (AEs);   Percentage of Participants with Serious Adverse Events (SAEs);   Percentage of Participants with Adverse Events of Special Interest (AESI);   Percentage of Participants with Any Adverse Event (AE) Leading to Withdrawal from the Study;   Percentage of Participants with Solicited Local Adverse Events (AEs) at Injection Site - Cohort 1;   Percentage of Participants with Solicited Systemic Adverse Events (AEs) - Cohort 1;   Percentage of Participants with Elevated Daily Oral Temperature - Cohort 1;   Percentage of Participants with Unsolicited Adverse Events (AEs) - Cohort 1;   Percentage of Participants with a Seroresponse (Pan-Ig ELISA);   Percentage of Participants with a Seroresponse of serum anti-norovirus GI.1 VLP (Pan-Ig ELISA);   Percentage of Participants with a Seroresponse of serum anti-norovirus GII.4 VLP (Pan-Ig ELISA);   Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA);   Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP(HBGA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA);   Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA);   Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA);   Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA);   Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA);   Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)
13 Recruiting Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
Condition: Exposure to Hepatitis B Virus
Interventions: Drug: HBsAg;   Biological: PreS HBsAg;   Biological: Advax-1(TM);   Biological: Advax-2(TM);   Biological: Advax-3(TM);   Biological: Alum
Outcome Measures: Safety;   Hepatitis B surface antibody geometric mean titer;   T cell responses;   Efficacy
14 Recruiting Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Condition: Vulvovaginal Candidiasis
Interventions: Biological: NDV-3A;   Biological: NDV-3;   Biological: Placebo
Outcome Measures: Safety and tolerability over the 12-months post vaccination period;   Recurrence of VVC over the 6-month post-vaccination period;   Humoral immune response over the 12-month post-vaccination period;   Cellular immune response over the 12-month post-vaccination period
15 Unknown  Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)
Condition: Malaria
Interventions: Biological: Lyophilised PEBS synthetic protein (PfPEBS);   Other: Rehydragel™ HPA
Outcome Measures: Adverse events following vaccination;   Change from baseline of antibodies active in the ADCI assay;   Parasitemia following mosquito challenge;   Antibodies against synthetic PEBS;   Antibodies against parasite antigen;   PEBS Interferon-Gamma
16 Unknown  Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor
Conditions: Peptic Ulcer;   Ulcer Complications
Interventions: Drug: lansoprazole;   Drug: aluminum hydroxide 334 mg and Mg hydroxide 166 mg
Outcome Measures: The primary end point is the occurrence of clinical upper GI events (symptomatic ulcer and ulcer complications-bleeding, perforation, or obstruction);   The secondary end point is occurrence of dyspepsia, asymptomatic gastroduodenal ulcers
17 Unknown  First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
Condition: Cutaneous Neurofibromas
Intervention: Procedure: Erbium-YAG laser vaporization
Outcome Measures: The aim of this study is to enhance the quality of life (measured by the Nottingham Health Profile the Rosenberg's Self-Esteem Scale and the SF-36 health survey) of patients suffering from disfigurement due to thousands of cutaneous neurofibromas.;   With this new method we want to decrease the painfulness, accelerated the time till wound healing as well as reduce the stay in hospital and the incidence of side effects.
18 Recruiting Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Condition: Cytomegalovirus Infections
Interventions: Biological: V160 Low Dose IM;   Biological: V160 Medium Dose IM;   Biological: V160 High Dose IM;   Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM;   Biological: V160 High Dose plus MAPA 225 µg /dose IM;   Biological: V160 Maximum Dose IM;   Other: Placebo IM;   Biological: V160 Medium Dose ID;   Other: Placebo ID
Outcome Measures: Percentage of Participants with an Adverse Event (AE);   Percentage of Participants with an Injection-site AE;   Percentage of Participants with a Systemic AE;   Percentage of Participants with a Serious Adverse Event (SAE);   Geometric Mean Titer of HCMV-specific Neutralizing Antibody;   Geometric Mean Count of Peripheral Blood Mononuclear Cells Secreting Interferon-Gamma;   Geometric Mean Concentration of Interferon-Gamma after Stimulation of Whole Blood Sample with Pooled HCMV Antigen Peptides
19 Recruiting Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Condition: Tuberous Sclerosis Complex
Intervention: Drug: RAD001
Outcome Measures: Evaluate the safety of RAD001 on neurocognition in patients with TSC compared with placebo in patients with TSC.;   To evaluate the efficacy of RAD001 on neurocognition in patients with TSC compared with placebo in patients with TSC.;   Comparison of absolute change from baseline in frequency of epileptiform events between patients taking RAD001 vs. placebo;   Comparison of sleep disturbances between patients taking RAD001 vs. placebo;   Comparison of autism spectrum disorders features between patients taking RAD001 vs. placebo;   Comparison of academic skills between patients taking RAD001 vs. placebo;   Comparison of behavioral problems between patients taking RAD001 vs placebo
20 Not yet recruiting Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.
Conditions: Virus Diseases;   RNA Virus Infections;   Respiratory Tract Diseases;   Respiratory Tract Infections
Interventions: Biological: Low dose of H7 VLP vaccine + Alhydrogel;   Biological: Med dose of H7 VLP vaccine + Alhydrogel;   Biological: High dose of H7 VLP vaccine + Alhydrogel;   Biological: High dose of H7 VLP vaccine;   Biological: Placebo
Outcome Measures: Safety;   Immunogenicity;   Immunogenicity 2;   Immunogenicity 3

These studies may lead to new treatments and are adding insight into Aluminium etiology and treatment.

A major focus of Aluminium research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Aluminium